Gourmey has achieved a landmark moment in cultivated meat production, becoming the first company in the sector to receive independent validation of a cost-effective and scalable model. A new techno-economic analysis by global consulting firm Arthur D. Little confirms that the Paris-based startup can produce cultivated meat at €7/kg ($3.43/lb) using its 5,000-liter bioreactor platform—currently the lowest cost reported in any third-party validated model.

The report from Arthur D. Little concludes that Gourmey’s second-generation production stack, centered on continuous processing and suspension-based cell cultures, is not only technically sound but economically grounded. By forgoing complex pharmaceutical-grade inputs and instead using food-grade processes, Gourmey’s system supports consistent output and global scalability without requiring massive capital expenditure or customized infrastructure.

“Gourmey’s platform was assessed to reach below €10/kg for finished product, the lowest cost level in publicly reported techno-economic models to date, [while] demonstrating best-in-class CapEx efficiency,” said Clément Santander, Partner at Arthur D. Little. “This marks a shift from potential to proof.”

The validated model includes:

• Production costs of €7/kg ($3.43/lb) at current 5,000L scale
• Capital expenditure below €35M per facility, with six bioreactors capable of yielding over 3 million pounds annually
• Continuous production at high cell density
• A feed cost of €0.20/L without the need for growth factors or fetal bovine serum
• Full suspension culture that eliminates scaffolds and microcarriers
• No dependence on pharmaceutical-grade materials

Gourmey’s market entry strategy is equally refined. Its debut product—cultivated foie gras—has already captured the attention of Michelin-starred chefs and a culinary advisory board stretching from Tokyo to San Francisco and Copenhagen. With premium foodservice partners eager to bring the product to market, demand has already exceeded Gourmey’s initial production forecasts.

‍

“Our focus has always been on building something technically sound, economically viable, and globally scalable to maximise our impact,” said Nicolas Morin-Forest, co-founder and CEO of Gourmey. “ The cultivated meat industry has reached a point where proof matters more than promises. This independent validation helps move the conversation forward to operational reality. It shows that, with the right technological choices supporting a realistic scale-up roadmap, cultivated proteins will become a meaningful solution to complement existing production systems.”

Gourmey’s platform is powered by a proprietary embryonic stem cell line and protected by over 50 patent filings, offering versatility across species and applications. The company’s pipeline includes additional poultry proteins and other meat types, supported by over €65 million in funding and regulatory filings underway in markets such as the EU, UK, Switzerland, Singapore, and the U.S.

With this third-party validation and scalable model in hand, Gourmey is preparing to enter global markets as one of the most technically advanced and commercially ready players in the cultivated meat space.